Hôpital d'Instruction des Armées Sainte-Anne

Background/Objectives: Pelvic injuries are frequently associated with severe hemorrhage and may contribute to early trauma-induced coagulopathy (TIC). Whether pelvic injury is independently associated with TIC beyond overall injury severity remains unclear. The objective of this study was to evaluate the association between pelvic injury and TIC in severe trauma patients. Methods: We conducted a retrospective single-center study including adult severe trauma patients (injury severity score > 15) admitted between January 2012 and July 2020. Patients with moderate to severe traumatic brain injury (because of its specific coagulopathy and mortality), inter-hospital transfer, pregnancy, or long-term anticoagulant or antiplatelet therapy were excluded. Pelvic injury was defined as any traumatic lesion involving the pelvic girdle identified on admission computed tomography. TIC was defined by an international normalized ratio (INR) > 1.2 and/or fibrinogen < 1.5 g/L and/or platelet count < 100 G/L. Multivariable logistic regression was performed to identify factors associated with TIC. Results: Among 388 included patients (79.6% male, median age 39 years), 114 (29.4%) had a pelvic injury. TIC was present in 160 patients (41.3%), and TIC prevalence was significantly higher in patients with pelvic injury (n = 73-64.0%) compared to those without (n = 87-31.8%) (p < 0.001). After multivariate analysis, TIC was independently associated with pelvic injury (OR 2.81, 95% CI 1.63-4.89), shock index > 0.9 (OR 1.94, 95% CI 1.12-3.37), hemoglobin < 10 g/dL (OR 4.27, 95% CI 1.77-11.49), and lower base excess values on admission (OR per unit increase 0.92, 95% CI 0.87-0.97). Injury severity score and number of lesions (AIS ≥ 3) were not independently associated with TIC. Conclusions: Pelvic injury was independently associated with TIC after adjustment for injury severity, number of severe injuries, and markers of hemodynamic and metabolic shock, including shock index, hemoglobin level, and base excess. These findings suggest that patients with pelvic injury may represent a high-risk subgroup for early coagulopathy, supporting the need for early recognition and adapted resuscitation strategies. Further prospective studies are required to explore underlying mechanisms.

Adjuvant immunotherapy improved patient outcomes in two trials in completely resected non-small cell lung cancer (NSCLC), but with conflicting primary end point results. The Canadian Cancer Trials Group BR.31 trial evaluated adjuvant durvalumab in completely resected early-stage NSCLC. Following resection of stage IB (≥4 cm) to IIIA NSCLC (American Joint Committee on Cancer 7th Edition) and optional adjuvant chemotherapy, patients were randomly assigned 2:1 to durvalumab 20 mg/kg or placebo 20 mg/kg once every 4 weeks for 12 cycles. Random assignment was stratified by stage, extent of nodal dissection, tumor cell (TC) PD-L1 expression, adjuvant chemotherapy use, and center. The primary end point was investigator-assessed disease-free survival (DFS). Secondary outcomes included overall survival (OS), adverse events, and quality of life. The primary analysis was in the subgroup with cancers that had a PD-L1 TC expression ≥25%, no common activating EGFR mutations (EGFR-), and no ALK gene rearrangements (ALK-). Secondary analyses in hierarchical order included DFS in the subgroup whose tumors were EGFR-/ALK- with PD-L1 TC ≥1%, followed by all patients whose tumors were EGFR-/ALK-, followed by OS in the same primary and secondary subgroups in the same hierarchical order. Of 1,415 patients randomly assigned, 1,219 (86%) had EGFR-/ALK- tumors: 815 randomly assigned to durvalumab and 404 to placebo. With a median follow-up of 60 months, there were no differences in DFS between patients assigned durvalumab (316) versus placebo (161) in the primary population (stratified hazard ratio [HR], 0.93 [95% CI, 0.71 to 1.25]; P = .64) or in the secondary populations. Grade 3 to 4 adverse events were higher in durvalumab-treated patients (D = 26% v P = 20%). Adjuvant durvalumab following complete resection was not associated with improvement in DFS compared with placebo in EGFR-/ALK- NSCLC, regardless of PD-L1 status.